Imbria Pharmaceuticals is a clinical stage biotechnology company developing novel therapies for cardiometabolic diseases.
Imbria Pharmaceuticals has raised $59.2M in total funding. The most recent round was Series B. The last funding was announced in April 2025.
Imbria Pharmaceuticals's investors include RA Capital Management, SV Health Investors, Catalio Capital Management, Cytokinetics, Deep Track Capital.
Imbria Pharmaceuticals is headquartered in Boston, United States.
Imbria Pharmaceuticals is a clinical stage biotechnology company developing novel therapies for cardiometabolic diseases.
Imbria Pharmaceuticals is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Imbria Pharmaceuticals — Funding & Investors." VCBacked, April 10, 2025, https://www.vcbacked.co/company/imbria-pharmaceuticals. Accessed July 19, 2026.
VCBacked. (2025). Imbria Pharmaceuticals — Funding & Investors. Retrieved July 19, 2026, from https://www.vcbacked.co/company/imbria-pharmaceuticals
{{cite web |title=Imbria Pharmaceuticals — Funding & Investors |url=https://www.vcbacked.co/company/imbria-pharmaceuticals |website=VCBacked |access-date=July 19, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated